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Abstract 
Background – The risk of peri-procedural stroke or death is higher following carotid artery stenting 
(CAS) than carotid endarterectomy (CEA) for the treatment of symptomatic carotid stenosis.  
However, long-term outcomes have not been sufficiently assessed. We sought to combine individual 
patient-level data from the four major randomised controlled trials of CAS versus CEA for the 
treatment of symptomatic carotid stenosis to assess long-term outcomes. 
Methods –Individual patient-level data was acquired from EVA3S, SPACE, ICSS, and CREST, the four 
largest randomised controlled trials assessing the relative efficacy of CAS and CEA for treatment of 
symptomatic carotid stenosis.  We did a pooled analysis to assess the risk of ipsilateral stroke 
between 121 days and 1, 3, 5, 7, 9, and 10 years after randomisation, as well as the composite risk of 
stroke or death within 120 days after randomisation, or subsequent ipsilateral stroke up to 10 years 
after randomisation.  Analyses were intention-to-treat, with the risk of events calculated using 
Kaplan-Meier methods, and Cox proportional hazards analysis with adjustment for trial.  
Findings – Of 4775 patients randomised, a total of 4754 patients were followed up for a maximum of 
12.4 years; 21 patients who immediately withdrew consent after randomization were excluded.  
Median length of follow-up across the studies ranged from 2.0 to 6.9 years.  There were 129 peri-
procedural and 55 post-procedural outcome events among those allocated CEA, and 206 and 57 for 
those allocated CAS.  The long-term outcomes after the peri-procedural period, the annual rates of 
ipsilateral stroke per person year, were similar for the two treatments, 0.60% (95% CI: 0.46 to 0.79) 
for CEA and 0.64% (95% CI: 0.49 to 0.83) for CAS.  Nonetheless, the peri- and post-procedural risks 
combined favoured CEA, with treatment differences at 1, 3, 5, 7 and 9 years all ranging between 
2.8% (95% CI: 1.1% to 4.4%) and 4.1% (95% CI: 2.0 to 6.3%). 
Interpretation – Long-term outcomes in the post-procedural period following CAS and CEA were 
similar, suggesting robust clinical durability for both treatments. Although long-term outcomes (per-
procedural and post-procedural risk combined) continue to favour CEA, the similarity of the post-
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procedural rates suggest that improvements in the peri-procedural safety of CAS could provide 
similar outcomes of the two procedures in the future. 
Funding – There was no funding supporting this analysis. 
 
Research in context 
Evidence before this study 
Over the last two decades four large randomised controlled trials (RCT) compared carotid stenting 
(CAS) to carotid endarterectomy (CEA) for prevention of stroke in symptomatic patients with 
moderate to severe carotid stenosis, the Endarterectomy versus Angioplasty in Patients with 
Symptomatic Severe Carotid Stenosis (EVA-3S) trial (n=527), the Stent-Supported Percutaneous 
Angioplasty of the Carotid Artery versus Endarterectomy (SPACE) trial (n=1200), The International 
Carotid Stenting Study (ICSS, n=1713), and The Carotid Revascularization Endarterectomy vs. 
Stenting Trial (CREST, n=1321 symptomatic patients).  We did not perform a new systematic 
literature search as part of this report; but since 2000, the only other completed RCT including more 
than 300 patients comparing CAS to CEA in recently symptomatic patients was the Stenting and 
Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) Trial (n=334); 
this study was not included in our analysis because it was performed in a different type of patient 
population (patients deemed at high risk for CEA, and only 96 were symptomatic). 
 
The Carotid Stenosis Trialists’ Collaboration (CSTC) previously reported short-term outcomes from 
pooled data from 3433 patients from the three largest European-based trials, EVA-3S, SPACE, and 
ICSS.  The risk of stroke or death within 120 days of the procedure was 8.9% for CAS and 5.8% for 
CEA (risk difference 3.2%; 95% CI 1.4–4.9%).    
 
Added value of this study 
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In this study, the CSTC-pooled patient-level data were expanded to include data from the US-Canada 
trial, CREST, increasing the sample cohort to 4754 patients. The previously reported treatment 
difference at 120 days after randomisation is numerically unchanged by the addition of CREST. 
Subsequent to the 120-day peri-procedural period, the ipsilateral stroke rates were similar 
(approximately 0.6% per person year) for patients treated with CAS and CEA for symptomatic carotid 
stenosis. The rates of ipsilateral stroke are lower than the annual rates of stroke outside the 
distribution of the target artery, and are also lower than the post-procedural rates reported for 
symptomatic and asymptomatic patients in earlier randomised trials. However, the combined peri- 
and post-procedural risks favoured CEA. 
 
Implications of all the available evidence    
This pooled analysis provides evidence to show that for both CEA and CAS, if performed safely, most 
revascularised patients can anticipate freedom from stroke up to 10-years following either CEA or 
CAS.  Nonetheless, the net long-term superiority of CEA over CAS as performed at the time of the 
four trials warrants the on-going efforts to improve the safety of CAS. Improvements in the peri-
procedural safety of CAS could provide similar outcomes of the two procedures in both the short 
and long-term. 
 
INTRODUCTION  
Randomized controlled trials of patients with recently symptomatic carotid stenosis have 
compared treatment with carotid artery stenting (CAS) with carotid endarterectomy (CEA)(1-5).   
Over a relatively short time horizon of two to three years following the procedures, individual 
studies have shown higher risk for the composite of peri-procedural stroke and death and 
subsequent ipsilateral stroke following CAS compared with CEA.  Because life expectancies for men 
and women of ages similar to those in these trials exceed 10-15 years, differences in the occurrence 
of stroke beyond two to three years are clinically meaningful (6).   
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The imprecision of the long-term data from individual studies fails to provide clinicians and 
patients with the information they need to make treatment decisions and to adjudge long-term 
prognosis. The number of patients followed for more than 5 years in individual trials was limited, 
363 patients in the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid 
Stenosis (EVA-3S) to this point, 596 from the International Carotid Study (ICSS), and 700 
symptomatic patients from Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST).  
There were no patients from the Stent-Protected Angioplasty versus Carotid Endarterectomy in 
symptomatic patients (SPACE) followed to 5 years. Accordingly, investigators representing the four 
major randomized trials – EVA-3S, SPACE, ICSS and CREST– have combined long-term outcome data 
of individual patients in a pooled analysis, which are reported in this paper. The primary outcome is 
the occurrence of ipsilateral stroke during the post-procedural period, beyond 120-days and out to 
10-years.  The peri- and post-procedural outcomes combined, the outcomes approximating the 
primary endpoints of the individual trials, are also analyzed.  Although the analyses were  pre-
planned, there is no published protocol available. 
 
METHODS 
Trials 
EVA-3S, SPACE, ICSS, and CREST were multicentre, randomised trials that compared 
outcomes following CAS and CEA of patients with moderate or severe atherosclerotic symptomatic 
stenosis at the carotid bifurcation(7).  The Carotid Stenosis Trialists’ Collaboration requested, 
received and harmonized the individual patient-level data for each of these trials.  These data have 
served as the bases for a series of reports including the current analysis.  CREST also enrolled 
patients with asymptomatic carotid stenosis who are not included in this analysis.  Stenosis eligibility 
was ≥ 60% in EVA-3S, ≥ 50% in SPACE, > 50% in ICSS, and ≥ 70% in CREST, all by duplex ultrasound 
and corresponding to angiographic values obtained with methods used in prior trials (CREST also 
allowed enrolment of patients with ≥ 50% stenosis by catheter angiogram). Patients were 
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randomised from November of 2000 through July of 2008.  Enrolment in EVA-3S was halted in 
September of 2005 per recommendation of the safety committee.(1) Enrolment in SPACE was also 
stopped prematurely following an interim analysis, for reasons of futility and lack of funding.(2)  
Each of the trials contributing data were reviewed and approved by the appropriate ethics 
committees. 
Credentialing and device use varied for carotid stenting, the experimental procedure. In 
EVA-3S, ICSS, and CREST interventionists had to have performed at least 12, 10, and 30 carotid-
stenting procedures respectively, and additional criteria varied. In SPACE, interventionists had to 
have performed at least 25 successful consecutive angioplasty or stent procedures, not necessarily 
of the carotid artery. Choice of stenting devices was at the discretion of the interventionist in EVA-
3S, SPACE, and ICSS. The use of approved cerebral protection devices was optional in SPACE and 
ICSS. Protection devices were made mandatory in EVA-3S after an interim analysis showed a higher 
risk of procedural stroke with unprotected stenting than with protected stenting (8). CREST required 
use of the ACCUNET® protection device, Abbott , Temecula, CA, USA, and the ACCULINK® stent, 
Abbott , Temecula, CA, USA. 
 
Outcome events 
The authors’ pre-defined main long-term outcome analysed is ipsilateral stroke during the 
post-procedural period.  Treatment differences at 1, 3, 5, 7,  9, and 10 years after randomization are 
reported.  These points were chosen arbitrarily without consideration of the specific pattern of 
treatment differences.  The pre-defined is the composite of stroke or death occurring within 120 
days after randomisation, or subsequent ipsilateral stroke(5). In the original reports of the individual 
trials, the periprocedural period was 0-30 days after CEA or CAS in EVA-3S, 0-30 days after 
randomisation in SPACE and CREST, and 0-120 days after randomisation in ICSS. The cutpoint for the 
peri- and post-procedural periods at 120 days after randomisation was chosen for the analyses here 
because in each contributing trial nearly all patients received their treatment within 3 months of 
8 
 
randomisation and received their post-treatment follow-up appointment within 4 months after 
randomisation. Accordingly, outcomes during this peri-procedural period of 0-120 days are also 
reported.  In addition to examining treatment differences at the above fixed time points, the hazard 
ratio over the entire follow-up period extending to the end of follow-up was considered.  Secondary 
outcomes include major stroke, minor stroke, and stroke in any distribution; for brevity the 
treatment differences for these secondary outcomes are provided only for the 5-year point in 
follow-up.  Additionally, analysis was performed for ipsilateral and non-ipsilateral stroke outcomes 
showing similar patterns to those reported herein, but these results are not reported in detail for 
reasons of brevity.   Stroke was defined as an acute neurologic event with focal symptoms and signs, 
lasting for 24 hours or more, that were consistent with focal cerebral ischaemia; visual loss resulting 
from retinal ischaemia that lasted for longer than 24 hours, was included within the category of 
stroke. None of the 4 trials used a tissue-based definition of stroke, and therefore patients with 
symptoms less than 24 hours in duration with positive MRI scans were not classified as stroke.  
Major stroke was defined in EVA-3S, SPACE, and ICSS as any stroke resulting in a modified Rankin 
scale of 3 or greater, 30 days or more after stroke onset. In CREST, major stroke was defined on the 
basis of clinical data or if the NIHSS score was 9 or higher 90 days after the randomization. Patients 
were evaluated neurologically after the procedure, and had follow-up evaluations at 30-36 days, 6 
months, and at least annually thereafter.  Potential outcome events were adjudicated by 
independent committees. Medical treatments followed standard of care, and patients were 
continued to be followed for stroke events after any carotid revasularization procedure.   
 
Data Analysis 
Analyses were intention-to-treat (ITT) and included all randomised patients, with the 
exception of 21 patients who immediately withdrew consent after randomization.  For both the peri-
procedural and post-procedural periods, the crude differences in the proportion of patients with 
events were assessed with Kaplan-Meier methods, and Cox proportional hazards analysis was used 
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to estimate CAS-to-CEA hazard ratios (HRs) after adjustment for the contributing trial. For the ITT 
analysis, the periprocedural period was defined as the first 120 days after randomisation.   All 
patients who had an event (stroke or death) or who withdrew from the studies during the peri-
procedural period were omitted from the post-procedural analysis, which started at 121 days after 
randomization.   The potential for a heterogeneity of treatment effect between studies was assessed 
by the introduction of a treatment-by-study interaction term to the proportional hazards model.  An 
additional per-protocol analysis was done, including only those patients in whom the first initiated 
revascularisation procedure after randomisation was the randomly allocated treatment. Patients 
crossing over to the alternative procedure, those remaining on medical treatment only, and patients 
who died before treatment were excluded from the per-protocol analysis. For the per-protocol 
analysis, the periprocedural period was defined as the first 30 days after revascularization, and the 
postprocedural period started at 31 days after revascularisation.  
 Subgroup analysis was performed where patients were stratified by covariates that 
potentially could affect CAS-CEA treatment differences, with treatment differences assessed for the 
entire follow-up (including both peri-procedural and post-procedural periods) and for the post-
procedural period alone.   Within each stratum, proportional hazards analysis was used to calculate 
the CAS-to-CEA hazard ratio after adjustment for the contributing trial, and the significance of 
potential treatment effect modification by the covariate was assessed by the addition of an 
interaction term to the proportional hazards model (statistical testing for interactions using an a 
priori α = 0.10). 
 
Role of funding source 
The funding agencies and companies that funded the original trials contributing to this 
analysis did not have access to the data, did not participate in the planning or funding of this 
analysis, and had no role in the preparation of this report.   
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RESULTS 
For the 4754 patients (Figure 1), maximum follow-up was 12.4 years in EVA-3S, 4.1 years in 
SPACE, 10.0 years in ICSS, and 10.2 years in CREST.  Median follow-up ranged between 2.0 to 6.9 
years (Table 1). About 30% of patients were females, three quarters had hypertension, and about 
70% were dyslipidaemic. About a quarter were current smokers, and 15% had severe (>=50-70%) 
contralateral carotid stenosis or occlusion (Table 1).    
The previously estimated peri-procedural 120-day stroke or death CAS versus CEA treatment 
difference from the 3 European trials was 3.2% (95% CI: 1.4% to 4.9%). (5)  In this analysis that 
included data from the CREST trial, this estimate is unchanged (3.2%), but with the increased sample 
size (now 4,754) tightening the 95% confidence bounds to 1.7% to 4.7% (Table 2).  
Beyond 120 days, the occurrence of stroke in the long-term was infrequent, and rates did 
not differ by CAS or CEA treatment at 5-years (Table 2), nor did the proportion of patients with 
events (Table 3). The absolute CAS versus CEA treatment difference in post-procedure stroke risk at 
years 1, 3, 5, 7 or 9 never exceeded 1%, ranging from -0.6% (95% CI: -1.6% to 0.4%) at year 3 to 0.6% 
(95% CI: -0.7% to 2.0%) at year 7.     Fifty-seven (57) ipsilateral strokes occurred in the CAS cohort, 
and 55 ipsilateral strokes occurred in the CEA cohort, CAS-to-CEA hazard ratio 1.06 (95% CI, 0.73 to 
1.54) (Table 2).  The annual rate of post-procedural ipsilateral stroke per person year was similar for 
CEA (0.60; 95% CI: 0.46 to 0.79) and CAS (0.64; 95% CI: 0.49 to 0.83) (Table 2). The rates of major 
stroke and minor stroke were also less than 1% per year (Table 2). These results out to 5 years (Table 
2) are consistent with the results out to 9 years (in Table 3) and the Kaplan-Meier curves (Figure 1 A-
H).  
 With the similarity of post-procedure stroke for those assigned to CAS and CEA, the 3.2% 
peri-procedural stroke risk was carried forward over the entire follow-up period, never differing 
from this initial treatment difference by more than 1% (Table 3, Figure 2B).  Over the entire follow-
up, the hazard for the primary event was 1.45-times (95% CI: 1.20 to 1.75) higher for those assigned 
to CAS (Table 2, Figure 2A). 
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 The post-procedure CAS versus CEA treatment differences were also quite small for major 
stroke (at 5-years: -0.2% with 95% CI -1.0% to 0.6%; HR = 0.86 with 95% CI: 0.48 to 1.56), minor 
stroke (at 5-years: 0.1% with 95% CI: -0.8% to 1.0%; HR = 1.21 with 95% CI: 0.75 to 1.96), and stroke 
in any distribution (at 5-years: 0.4% with 95% CI: -1.5% to 2.3%; HR = 1.08 with 95% CI: 0.84 to 1.38 
(Table 2)).   Among all strokes (both major and minor), 112 (43%) of the 259 post-procedural strokes 
were in the distribution of the artery targeted for CAS or CEA, and 147 (57%) were outside that 
distribution (i.e. either contralateral or in the posterior circulation).    
The homogeneity of treatment effects across studies was assessed by the addition of a trial-
by-treatment interaction term to the proportional hazards models.   A total of 12 interaction terms 
were considered when the 4 outcomes (primary outcome, major stroke, minor stroke, and all stroke 
outcome) were considered for 3 periods (peri + post-procedural periods, peri-procedural, post-
procedurals).   Of these 12 interactions, 1 was just marginally significant (p = 0.040) for the overall 
period, which was considered likely a spurious finding arising from multiple testing. 
The results of the subgroup analysis are shown in Figure 3.   The analysis of the entire follow-
up period (all stroke in both peri-procedural and post-procedural) confirmed the previously reported 
lower risk of treatment by CEA compared to CAS in older patients, with similar risks in younger 
patients (pinteraction = 0.003).   With a significant interaction with treatment, smoking (pinteraction = 
0.022) and the presence of contralateral severe stenosis (pinteraction = 0.040) also were documented as 
effect modifiers.   There was no evidence of a treatment difference for smokers (HR = 0.93; 95% CI: 
0.61 – 1.41), while among non-smokers the risk was higher for treatment with CAS (HR = 1.61; 95% 
CI: 1.30 – 1.99).    Likewise, there was no evidence of a treatment effect for patients with a severe 
contralateral stenosis (HR = 1.01; 95% CI: 0.65 – 1.58), while among those without a contralateral 
stenosis the risk was higher for treatment with CAS (HR = 1.69; 95% CI: 1.35 – 2.13).  During the 
post-procedural period, the CAS-to-CEA treatment differences were not significant within any 
stratum defined by any covariate, and there was no evidence of treatment effect modification (or 
interaction with treatment) by any covariate (pinteraction ≥ 0.134)  
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Results of the per-protocol (PP) analysis were generally similar to those of the ITT analysis. 
Using the significance of associations as criteria, there were no differences between the ITT and PP 
analyses that would affect interpretation of the primary outcome, minor stroke, or stroke in any 
distribution.  However, for major stroke, the per-protocol analysis showed a significant treatment 
difference both for all events (HR = 1.41; 95% CI: 1.02 - 1.94) and during the peri-procedural period 
(HR = 1.63; 95% CI: 1.10 – 2.43); while in contrast the ITT analysis was not significant for either all 
events (HR = 1.23; 95% CI: 0.91 – 1.66) or for the peri-procedural period (HR = 1.39; 95% CI: 0.98 – 
1.97).  
 
DISCUSSION 
This pooled analysis shows that the long-term (i.e., post-procedural) durability of CAS and 
CEA are remarkably similar with the annual rate of ipsilateral stroke per person year at 0.60% for 
CEA and 0.64% for CAS. Hence, patients remaining event-free during the peri-procedural procedural 
period are similarly served by the CAS and CEA interventions.  Nonetheless, the higher early risks 
following CAS are such that the primary outcome of any stroke or death out to 120 days and 
ipsilateral stroke thereafter favours CEA, even out to 10 years (HR=1.45; 95% CI, 1.20 to 1.75). 
These results suggest the importance of on-going improvements in the peri-procedural 
safety of CAS, (9) including changes in CAS technology and stenting techniques and the careful 
selection of appropriate patients for the procedure.  For example, we have previously reported that 
the majority of excess risk among those assigned to CAS is at older ages (10).  As such, preferentially 
employing CAS in younger patients (i.e. age <65 years) could improve periprocedural safety. 
The rates of long-term post procedural events reported here are low compared to prior 
trials for stroke preventions.  If the estimated risks from Kaplan-Meier curves from the NASCET study 
are annualized, the post-procedural annual risk for any stroke was 4.5%.(11)  The comparable risk in 
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the 4 trials reported here is 1.4% for CEA and 1.5% for CAS.  Comparable data are not available for 
the symptomatic patients reported in the European Carotid Surgery Trial (ECST).  
We do not suggest that the low long-term stroke rates herein result solely from 
revascularization with CEA or CEA. Risk factor control likely plays a more important role. (12). In the 
Asymptomatic Carotid Surgery Trial (ACST),(13)  those on lipid lowering drugs at baseline had an 
annual rate of long-term stroke after the periprocedural period  of 0.6% compared with 1.5% for 
those not on lipid lowering drugs.  Only 9% of the patients were on lipid lowering drugs the first year 
of enrolment in ACST in 1993, and 81% were on antihypertensive drugs.  By the end of enrolment in 
2003, 81% were on lipid lowering drugs, and 88% were on antihypertensive drugs.  
The subgroup analysis in our pooled analysis of the entire follow-up period (all stroke in both 
peri-procedural and post-procedural) confirmed the previously reported lower risk for stroke of CEA 
(relative to CAS) in older patients (14), and also identified both smoking and the presence of 
contralateral stenosis as treatment effect modifiers (i.e., having an interaction with treatment).   The 
apparent differential effect between strata defined by smoking is likely because of the confounding 
of age with smoking, where the average age of smokers tends to be much lower than that of non-
smokers. The effect modification by the presence of contralateral stenosis requires additional 
investigation.    
As there were only 112 post-procedural events, the subgroup analysis of treatment 
differences during this period should be interpreted with caution.   However, the analysis presented 
in Figure 3 failed to detect a significant treatment difference in the post-procedural period for any 
stratum for any covariate, and there was not significant evidence of effect modification by any 
covariate; hence, it appears the similar risk for CAS and CEA during the post-procedural period is 
consistent for these subgroups of patients. 
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The advantages of this pooled analysis with individual patient data include wider 
generalizability and improved precision.  Patients, surgical, interventionist, and medical teams from 
multiple countries and three continents participated.  Combination of the four trials provided 4754 
patients for analysis, allowing stable long-term estimates of the peri-procedural risks and 
subsequent clinical durability for CAS and CEA as well as allowing meaningful subgroup analyses 
possible; these results are the most precise available.  Disadvantages include variability in surgical 
and interventionist training and experience, differences in outcome ascertainment and adjudication, 
and in intensity of patient follow-up examinations and medical treatment. A limitation of any long-
term post-procedural outcome analysis is that by definition the procedures had to be performed 
long ago, in this case more than a decade ago. Another limitation is that we limited our analyses to 
first strokes, hence our report does not inform on the risk of recurrent strokes.  However, 112 
ipsilateral first-strokes occurred during the periprocedural period; if those patients had the very high 
5-year recurrence risk for any stroke noted for NASCET (4.5%),(11) only an additional 6 recurrent 
strokes would have been detected. 
In summary, this pooled analysis of the four major RCTs comparing CEA and CAS 
demonstrates that if these procedures are performed safely, most revascularised patients can 
anticipate freedom from stroke at 10-years following either CEA or CAS.  Nonetheless, the net long-
term superiority of CEA over CAS as performed in the last decade warrants the improvements in the 
procedural safety of CAS that are ongoing.  Accordingly, while the combined peri-procedural and 
post-procedural outcome results continued to favour CEA, the similarity of the post-procedural rates 
suggest that improvements in the peri-procedural safety of CAS could provide similar outcomes of 
the two procedures.  The mechanisms of the post-procedural strokes that occurred over the long-
term remain to be established.  
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Overall Source Trial 
CEA CAS EVA-3S SPACE ICSS CREST 
Number of Patients 2361 2393 527 1196 1710 1321 
Age (years) (median / (p25 
p75)) 
70 
(63 – 77) 
70 
(63 – 76) 
72 
(64 – 78) 
68 
(62 – 75) 
71 
(64 – 77) 
70 
(62 – 76) 
Female (k/n (%)) 
702/2361 
(30) 
735/2393 
(31) 
130/527 
(25) 
338/1196 
(28) 
503/1710 
(29) 
446/1321 
(35) 
Hypertension (k/n (%)) 
1782/2350 
(76) 
1792/2381 
(75) 
383/527 
(73) 
904/1196 
(76) 
1183/1694 
(70) 
1104/1314 
(84) 
Diabetes (k/n (%)) 
602/2356 
(26) 
591/2390 
(25) 
126/527 
(24) 
326/1196 
(27) 
372/1710 
(22) 
369/1313 
(28) 
Dyslipidaemia (k/n (%)) 
1231/1757 
(70) 
1186/1771 
(67) 
300/527 
(57) 
† 
1085/1694 
(64) 
1032/1307 
(79) 
Current Smoking (k/n (%)) 
613/2340 
(26) 
606/2373 
(26) 
126/527 
(24) 
325/1196 
(27) 
403/1694 
(24) 
365/1296 
(28) 
Previous Ischaemic Heart 
Disease (k/n (%)) 
656/2303 
(28) 
637/2338 
(27) 
93/527 
(18) 
269/1196 
(22) 
467/1694 
(28) 
464/1224 
(38) 
Severe ipsilateral stenosis (k/n 
(%)) 
1896/2361 
(80) 
1939/2393 
(81) 
491/527 
(93) 
741/1196 
(62) 
1542/1710 
(90) 
1061/1321 
(80) 
Severe contralateral stenosis or 
occlusion (k/n (%)) 
314/2115 
(15) 
312/2139 
(15) 
69/527 
(13) 
100/927 
(11) 
301/1697 
(18) 
156/1103 
(14) 
Rankin 0 (k/n (%)) 
1172/2335 
(50) 
1200/2370 
(51) 
288/527 
(55) 
635/1196 
(53) 
675/1680 
(40) 
774/1302 
(59) 
Length of 
Follow 
Up (years) 
 
 
N 2361 2393 527 1196 1710 1321 
Mean ± SD 4.2 ± 2.9 4.0 ± 3.0 6.2 ± 3.2 1.7 ± 0.7 4.0 ± 2.1 5.6 ± 3.4 
Median  
(IQR) 
3.6  
(2.0 – 6.4) 
3.4 
(2.0 – 6.2) 
6.9 
(3.8 – 8.6) 
2.0 
(2.0 – 2.0) 
4.1 
(3.0 – 5.2) 
6.2 
(2.7 – 8.6) 
Table 1: Description of the study population by treatment assignment and by contributing study.   
 
†Dyslipidaemia data was not available in the SPACE trial. 
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All Events  
(nCEA = 2361; nCAS = 2393) 
Peri-Procedural Events (Within 120 Days) 
(nCEA = 2361; nCAS = 2393) 
Post-Procedural Events (After 120 Days) 
(nCEA = 2168; nCAS = 2121) 
# Events /  
(%) 
Rate at 5-
years  
Absolute  
risk diff at 
5-years 
Hazard 
Ratio  
(95% CI) 
# Events /    
(%) 
Rate at 120 
days 
Absolute  
risk diff at 
120 days 
Hazard 
Ratio  
(95% CI) 
# Events /  
(%) 
Rate at 5-
years  
Absolute  
risk diff at 
5-years 
Hazard 
Ratio  
(95% CI) 
Annual Event 
Rate Per 
Person-Year 
(95% CI) 
Any stroke or 
death within 120 
days + ipsi stroke 
afterwards 
CEA 
184 
(7.8) 
8.3 
(7.2 to 9.6) 3.0 
(1.2 to 4.8) 
1.45 
(1.20 to 1.75) 
129 
(5.5) 
5.5 
(4.7 to 6.5) 3.2 
(1.7 to 4.7) 
1.61 
(1.29 to 2.01)  
55 
(2.5) 
3.0 
(2.3 to 3.9) -0.1 
(-1.3 to 1.1) 
1.06 
(0.73 – 1.54) 
0.60 
(0.46 to 0.79) 
CAS 
263 
(11.0) 
11.4 
(10.1 to 12.8) 
206 
(8.6) 
8.7 
(7.6 to 9.9) 
57 
(2.7) 
2.9 
(2.1 to 3.9) 
0.64 
(0.49 to 0.83) 
Any major stroke 
within 120 days + 
major ipsilateral 
afterwards 
CEA 
79 
(3.4) 
3.7 
(2.9 to 4.6) 0.7 
(-0.5 to 2.0) 
1.23 
(0.91 – 1.66) 
55 
(2.3) 
2.4 
(1.8 to 3.1) 1.0 
(-0.0 to 1.9) 
1.39 
(0.98 – 1.97) 
24 
(1.1) 
1.3 
(0.9 to 2.0) -0.2 
(-1.0 to 0.6) 
0.86 
(0.48 to 1.56) 
0.26 
(0.18 to 0.39) 
CAS 
96 
(4.0) 
4.4 
(3.6 to 5.4) 
76 
(3.2) 
3.3 
(2.6 to 4.1) 
20 
(0.9) 
1.2 
(0.7 to 1.9) 
0.22 
(0.14 to 0.35) 
Any minor stroke 
within 120 days + 
minor ipsilateral 
afterwards 
CEA 
88 
(3.7) 
4.1 
(3.3 to 5.1) 2.2 
(0.9 to 3.6) 
1.67 
(1.28 to 2.17) 
57 
(2.4) 
2.5 
(1.9 to 3.2) 2.2 
(1.1 to 3.2) 
1.91 
(1.39 to 2.63) 
31 
(1.4) 
1.7 
(1.2 to 2.4) 0.1 
(-0.8 to 1.0) 
1.21 
(0.75 to 1.96) 
0.34 
(0.24 to 0.48) 
CAS 
145 
(6.1) 
6.3 
(5.3 to 7.5) 
108 
(4.5) 
4.7 
(3.9 to 5.6) 
37 
(1.7) 
1.8 
(1.2 to 2.6) 
0.41 
(0.30 to 0.57) 
Stroke in any 
distribution  
CEA 
238 
(10.1) 
11.1 
(9.8 to 12.7) 3.1 
(0.9 – 5.2) 
1.35 
(1.15 – 1.60) 
112 
(4.7) 
4.8 
(4.0 to 5.7) 3.0 
(1.6 to 4.4) 
1.66 
(1.32 to 2.10) 
126 
(5.8) 
6.9 
(5.7 to 8.3) 0.4 
(-1.5 to 2.3) 
1.08 
(0.84 to 1.38) 
1.38 
(1.16 to 1.65) 
CAS 
318 
(13.3) 
14.2 
(12.7 to 15.9) 
185 
(7.7) 
7.8 
(6.8 to 9.0) 
133 
(6.3) 
7.3 
(6.0 to 8.8) 
1.49 
(1.25 to 1.76) 
Table 2:  Event rates over the entire follow-up, within the peri-procedural period, and during the post procedural period.   For all events and for events during the post procedural period the 
table provides: 1) the number and proportion of patients with events, 2) the event rate at 5-years (with 95% confidence intervals) estimated from Kaplan-Meier analysis, 3) the difference in the 
Kaplan-Meier event rate (with 95% confidence interval), and 4) the CAS-to-CEA hazard ratio (with 95% confidence intervals).   For the post-procedural period, the table also provides the annual 
event rate (with 95% confidence intervals).    For the peri-procedural period, the table provides similar statistics but with the rates estimated at 120-days after randomization (rather than at 5-
years). 
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Outcome Treatment 
Years post-randomization 
1 3 5 7 9 
Long-term 
Outcome  
(peri + post) 
(%: 95% CI) 
CEA 
6.4 
(5.4 to 7.4) 
7.7 
(6.7 to 8.9) 
8.3 
(7.2 to 9.6) 
8.4 
(7.3 to 9.7) 
8.7 
(7.5 to 10.0) 
CAS 
9.5 
(8.4 to 10.8) 
10.5 
(9.3 to 11.8) 
11.4 
(10.1 to 12.8) 
12.1 
(10.7 to 13.7) 
12.5 
(11.2 to 14.6) 
CAS – CEA 
Difference 
3.1 
(1.6 to 4.7) 
2.8 
(1.1 to 4.4) 
3.0 
(1.2 to 4.8) 
3.7 
(1.8 to 5.6) 
4.1 
(2.0 to 6.3) 
Post-
Procedure  
Durability 
(post only) 
(%: 95% CI) 
CEA 
1.2 
(0.8 to 1.7) 
2.6 
(2.0 to 3.5) 
3.1 
(2.3 to 4.1) 
3.1 
(2.3 to 4.1) 
3.9 
(2.7 to 5.8) 
CAS 
1.0 
(0.6 to 1.5) 
2.0 
(1.5 to 2.8) 
3.2 
(2.3 to 4.2) 
3.7 
(2.8 to 5.0) 
4.5 
(3.2 to 6.2) 
CAS – CEA 
Difference 
-0.2 
(-0.8 to 0.4) 
-0.6 
(-1.6 to 0.4) 
0.0 
(-1.2 to 1.3) 
0.6 
(-0.7 to 2.0) 
0.5 
(-1.6 to 2.7) 
Table 3: Event rates for primary event outcome and ipsilateral post-procedural stroke by treatment 
assignment (with 95% confidence interval), and differences in treatment (with 95% confidence interval) at 1, 
3, 5, 7 and 9 years. 
 
